NASD · Healthcare · Biotechnology · Canada
AbCellera Biologics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
AbCellera Biologics is a clinical-stage biotechnology company discovering and developing antibody-based treatments for diseases with unmet medical needs. The company has built a platform for creating drug candidates targeting difficult receptors, multispecific molecules, and antibody-drug conjugates. It currently has two candidates in clinical testing and two in preparatory development across women's health, immunology, autoimmunity, and oncology.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the AbCellera Biologics Inc stock.
Overvalued: intrinsic value $1.04 per share, market price $12.27, margin of safety -1075.7% (as of 2026-10-30).
Its liquidation floor, current assets minus every liability, values the shares at $1.04; the price of $12.27 is 1076% above that value.
3 more funds hold it; the full list is part of the paid plan.
113 more in this industry show a wider margin of safety.
ABCL is overvalued (as of the 2026-10-30 close). Its liquidation floor, current assets minus every liability, values the shares at $1.04; the price of $12.27 is 1076% above that value.
$1.04 per share (as of the 2026-10-30 close), against a market price of $12.27. That is a margin of safety of -1075.7%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.